Pharvaris to Present Clinical and Nonclinical Data at Upcoming Congresses
2024-05-13
临床2期临床3期
Pharvaris to Present Clinical and Nonclinical Data at Upcoming Congresses
ZUG, Switzerland, May 13, 2024 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a late-stage biopharmaceutical company developing novel, oral bradykinin B2 receptor antagonists to treat and prevent hereditary angioedema (HAE) attacks, today announced the acceptance of abstracts for presentation at three upcoming congresses: the 20th Annual Congress of International Drug Discovery Science and Technology (IDDST); the 2024 Eastern Allergy Conference (EAC); and the European Academy of Allergy and Clinical Immunology (EAACI) Congress 2024. Details of the presentations are as follows:
IDDST 2024. Osaka, Japan. May 22-24, 2024.
Title: Pharmacological Profile of Deucrictibant, a Small-molecule Bradykinin B2 Receptor AntagonistBradykinin B2 Receptor Antagonist in Clinical Development for Hereditary Angioedema
Presenter: Anne Lesage, Ph.D.
Format: Oral Presentation
Date, time: Wednesday, May 22, 10:55-11:20 a.m. JST (Tuesday, May 21, 9:55-10:20 p.m. EDT)
EAC 2024. Palm Beach, Florida, U.S. May 30-June 2, 2024.
Title: Relief and Resolution of Attack Symptoms Following On-Demand Treatment With a Single Dose of Oral Bradykinin B2 Receptor Antagonist Deucrictibant Immediate-Release Capsule in Patients With Hereditary Angioedema
Presenter: Henry Li, M.D., Ph.D.
Format: Poster Presentation
Date, time: Saturday, June 1, 9:45-11:00 a.m. EDT
EAACI Congress 2024. Valencia, Spain. May 31-June 3, 2024.
Title: Efficacy and Safety of Oral Deucrictibant, a Bradykinin B2 Receptor AntagonistBradykinin B2 Receptor Antagonist, in Prophylaxis of Hereditary Angioedema Attacks: Results of CHAPTER-1 Phase 2 Trial
Presenter: Emel Aygören-Pürsün, M.D.
Format: Oral Presentation
Date, time: Saturday, June 1, 17:21 CEST (11:21 a.m. EDT)
Title: Prophylactic Treatment with Oral Deucrictibant Improves Health-Related Quality of Life of Patients with Hereditary Angioedema
Presenter: Anna Valerieva, M.D., Ph.D.
Format: Oral Presentation
Date, time: Saturday, June 1, 17:33 CEST (11:33 a.m. EDT)
Title: Efficacy and Safety of the Oral Bradykinin B2 Receptor Antagonist Deucrictibant Immediate-Release Capsule in Treatment of Hereditary Angioedema Attacks: RAPIDe-3 Phase 3 Trial Design
Presenter: Marcus Maurer, M.D.
Format: Poster (Flash Talk) Presentation
Date, time: Sunday, June 2, 13:15 CEST (7:15 a.m. EDT)
Title: Exploring the Relationship Between Airway Attacks and Patient-Reported Outcomes in Hereditary Angioedema Attacks
Presenter: Laurence Bouillet, M.D., Ph.D.
Format: Poster (Flash Talk) Presentation
Date, time: Sunday, June 2, 13:15 CEST (7:15 a.m. EDT)
Title: Pharmacodynamic Effects of Deucrictibant on Carrageenan-induced Edema in Humanized Bradykinin B2 Receptor Transgenic Sprague Dawley Rat
Presenter: Anne Lesage, Ph.D.
Format: Poster (Flash Talk) Presentation
Date, time: Sunday, June 2, 13:15 CEST (7:15 a.m. EDT)
Title: Development of Kallikrein-Kinin System Biomarker Assays to Investigate Bradykinin-mediated Diseases
Presenter: Evangelia Pardali, Ph.D.
Format: Poster (Flash Talk) Presentation
Date, time: Sunday, June 2, 13:15 CEST (7:15 a.m. EDT)
Abstracts from the EAACI Congress will be published in Allergy (the European Journal of Allergy and Clinical Immunology) after the Congress. The posters and presentation slides will be made available on the Investors section of the Pharvaris website at the beginning of the respective presentation sessions at: https://ir.pharvaris.com/news-events/events-presentations.
About Pharvaris
Building on its deep-seated roots in HAE, Pharvaris is a late-stage biopharmaceutical company developing novel, oral bradykinin B2 receptor antagonists to treat and prevent HAE attacks. By directly pursuing this clinically proven therapeutic target with novel small molecules, the Pharvaris team aspires to offer people with all sub-types of HAEHAE efficacious, safe, and easy-to-administer alternatives to treat attacks, both on-demand and prophylactically. The company brings together the best talent in the industry with deep expertise in rare diseases and HAE. For more information, visit https://pharvaris.com/.
更多内容，请访问原始网站
文中所述内容并不反映新药情报库及其所属公司任何意见及观点，如有版权侵扰或错误之处，请及时联系我们，我们会在24小时内配合处理。
热门报告
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。